Ryvu Therapeutics S.A.,
2 Sternbacha Street, 30-394 Krakow, is registered in the District Court for the Krakow-Srodmiescie in Krakow XI Division of the National Court Register

KRS number: 0000367359
Reg. No. 120515330
VAT ID: PL6792942955
Share capital: PLN 9,248,059.20 (paid in full)

Krakow, 3rd March 2023

REQUEST FOR PROPOSAL No. AMB-03032023-CRO

In connection with the planned implementation by Ryvu Therapeutics S.A. of the project 'The conduct of a phase II, multicentre, open-label clinical trial (RIVER-81) evaluating the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia who have failed prior therapy with venetoclax and a hypomethylating agent' (the 'Project') under the Competition: Development of targeted or personalized medicine based on therapeutic products based on nucleic acids and small-molecule compounds ABM/2022/6 organized by the Medical Research Agency, Ryvu Therapeutics S.A. invites quotes for the execution of the following defined subject of the request.

I. ORDERING PARTY/SPONSOR

Ryvu Therapeutics S.A.
Sternbacha 2, 30-394 Krakow, Poland
EU VAT PL6792942955
in the further content of the RFP, hereinafter referred to as the 'Ordering Party' or 'Sponsor'.

II. SUBJECT OF THE REQUEST

This subject of the request concerns the operational execution and reporting of the study, country and site feasibility, site identification and evaluation and applicable submissions to Regulatory Authorities and Ethics Committees of a phase II clinical study of a study drug in combination with a market drug in patients with AML/HR-MDS.

Sponsor's study assumptions

The Sponsor's assumptions on the studies are provided below. CRO's assumptions, regarding the number and location of sites (including contingency sites) are to be proposed based on previous experience and current prognosis. A rationale for choice should be provided.

Table 01.

Number of Subjects (evaluable):	98
Prescreen/ Screen failure rate:	CRO to provide
Drop-out rate/non-evaluable:	CRO to provide
Countries pre-selected by the Sponsor:	Poland, Spain, Italy, Romania, Bulgaria, Serbia, Germany, Belgium, US
Number of countries to be proposed by CRO:	at least 1
Number of sites:	minimum 10 sites per country to be identified; 5 sites per country evaluated/selected
Sponsor`s desired study start (first patient dosed):	01-Sep-2023
Targeted enrollment completed:	01-Sep-2024

The final decision regarding the type and number of countries in which the study will be conducted will be made by the Sponsor. A list of 10 recommended centers should be provided, from which Ryvu will select 5 for the next step (evaluation).

General task description

Table 02.

Activities	
1	**Project Management** • Project oversight plan (including, but not limited to communication plan, risk identification and management plans, regulatory submission plan), • Ongoing Project Management; to include monthly project status and budget utilization reporting.
2	**Country/site selection and feasibility** • Study feasibility (comments/input on study feasibility to be provided as a part of Quotation), • Countries and sites identification and feasibility (see details in Table 01.), • Sites qualification visits conduct and reporting, • Start-up activities in selected countries/sites (after Ryvu selection confirmed on countries and sites); this to include all activities required for selected sites initiation (SIV of the sites is not a in scope of this RFP), • Sites contracts and budget negotiations/finalization/signatures.
3	**Study Materials and tools preparation** • Informed Consent Form (Master and country customizations, translation and translation review), • Patient facing materials: Patient Cards, Diaries, etc. (country level customization), • Any other required for the study CA/RA submission.
4	**Regulatory Affairs and Ethics Committee** • Initial CTA preparation, essential documents collection, submission, coordination and tracking in all the selected countries (both EC and Competent Authority).
5	**Pass Through costs** • Travel cost and expenses (site visits), • EC/CA submission fees, • Investigator/site fees (as applicable, e.g. site start-up fee), • Licensing fees (as applicable), • Shipments, Translations, etc.
6	**Other necessary to perform**

III. CONDITIONS FOR PARTICIPATION IN THE PROCEEDINGS

III.1. Bidders that can declare the following are invited to submit quotations: operational readiness to submit the study to Regulatory Authority and Ethics Committee by 1st of June 2023.

III.2. Bidders that have the following are invited to submit quotations: Phase I/II hematology clinical studies experienced team (permanent employees) in the countries pre-selected by the Sponsor (Poland, Spain, Italy, Romania, Bulgaria, Serbia, Germany, Belgium, US) as well in the countries proposed by CRO.

III.3. Bidders that are invited to submit quotations must be engaged in activities consistent with the subject of the request and have experience in the field of Phase I/II hematologic clinical studies – at least 5 global phase I/II studies started for different sponsors in the last 3 years counted up to the date of publication of this Request for Quotation, and if the period of doing business is shorter during this period.

III.4. Bidders that have the following are invited to submit quotations: CRO's permanent employees:

- Project Manager with min. 5 years of professional experience as Project Manager of Phase I/II hematology clinical studies,
- Regulatory Manager with min. 5 years of professional experience.

The period of professional experience required in this section should be counted up to the date of publication of this Request for Quotation. Bidders are obliged to submit resumes (CVs) of the above-mentioned persons.

IV. PLACE, DATE AND PROCEDURE OF SUBMISSION OF QUOTES

IV.1. The proposal must be submitted by: **17th March 2023 at 23.59 CET**.

IV.2. The proposal must be sent via e-mail to the following address: tenders@ryvu.com. The message with the offer should refer to the RFP number indicated on the first page: **AMB-03032023-CRO**.

IV.3. The proposal and its attachments should be prepared in English.

IV.4. The proposal should be prepared in an accordance with the form constituting Appendix 01 to this RFP and should include the following information:

- detailed description of the work given in the CRO budget grid as an unitized budget. Units` composition should be provided (number of hours and resource allocation per unit); provided in an MS Excel file, prices given in EUR, cost has to be grouped with functional areas in accordance with Table 02 of RFP no. AMB-03032023-CRO. Any cost not covered is to be added as an additional cost group 'Other necessary to perform'. (Time and Material costing is acceptable). A final list of deliverables, roles and responsibilities and project timelines will be agreed in the course of signing the agreement and described in the assigned Work Oder (or equivalent).s an alternative scenario a fix price budget may be provided in addition to a unitized one.
- current reporting (frequency and way of updates/meetings, data format, documentation, etc.) during the course of the service, a list of all study manuals, plans, guidelines and trackers that will be generated for this study, a description of team structure (organizational chart), project management, process overview, and communication/escalation plan, metrics used by a CRO and provided to the study sponsor on performance and compliance verification.
- if the services offered are provided by direct employees of the CRO, freelance contractors, or other form of sub-vendor(s).
- a description of CRO's experience in the field of hematology, Phase I/II clinical studies in the last 5 years.
- all other relevant background information and strategic approaches presenting CRO's eligibility to execute the studies.

IV.5. **The Bidders must provide the total price for the execution of the order (total fees including direct, indirect and pass throughs costs) consisted with the subject of the request. The proposal must include prices given in EUR.**

V. ADDITIONAL INFORMATION

V.1. The Bidders may ask the Ordering Party to clarify the content of this RFP. If the request for clarification of the content of the RFP was received later than by the end of 13th March 2023, the Ordering Party may provide explanations or leave the application unexamined. Questions must be sent to the following e-mail address: tenders@ryvu.com.

V.2. Due to the need to protect business secrets, in the event of questions requiring the disclosure of confidential data, the Ordering Party reserves the right to provide explanations after signing and sending by e-mail by the Bidder the Confidential Disclosure Agreement (CDA). It is allowed to use an electronic signature (including a qualified electronic signature), a trusted signature (trusted profile). The CDA document will be made available at the request of the Bidder by e-mail. The scan of the completed and signed CDA should be sent to the indicated e-mail address: tenders@ryvu.com.

V.3. The Ordering Party reserves the right to change the content of the RFP, including changes in the terms of the procedure. Bidders will be informed.

V.4. The Ordering Party reserves the right to ask the Bidders at any stage of the evaluation of offers for additional information, documents, additions or explanations. The Ordering Party's contact with the Bidder will take place by e-mail indicated in the content of the offer sent by the Bidder.

V.5. This RFP does not oblige the Ordering Party to conclude a contract.

V.6. For more information, please contact Aleksandra Mazgała or Anna Dziedzicka at the following email address: tenders@ryvu.com.

ATTACHMENTS

Appendix 01 – THE PROPOSAL FORM

APPENDIX 01 TO AMB-03032023-CRO

THE PROPOSAL FORM

Data of the Bidder Name:	
Address:	
Tax ID/EU VAT:	
Person authorized to contact the Ordering Party: name and surname:	
e-mail address:	

1. We confirm that the scope of the service offered is consistent with the description of the subject of the request no. AMB-03032023-CRO .
2. W declare operational readiness to submit the study to Regulatory Authority and Ethics Committee by 1st of June 2023.
3. We declare possession of Phase I/II hematology clinical studies experienced team (permanent employees) in the countries pre-selected by the Sponsor (Poland, Spain, Italy, Romania, Bulgaria, Serbia, Germany, Belgium, US) as well in countries proposed: …… .
4. We declare being engaged in activities consistent with the subject of the request and have experience in the field of Phase I/II hematologic clinical studies – at least 5 global phase I/II studies started for different sponsors in the last 3 years counted up to the date of publication of this RFP, and if the period of doing business is shorter during this period.

Ordinal number	Sponsor type	Date (start and end) and place of execution	Clinical indication/study phase
1			
2			
3			
4			
5			

5. We declare possession of CRO's permanent employees:

Ordinal number	Employee	Name and surname
1	Project Manager with min. 5 years of professional experience as Project Manager of Phase I/II hematology clinical studies	
2	Regulatory Manager with min. 5 years of professional experience	

The period of professional experience required in this section should be counted up to the date of publication of this Quote Request. The resumes (CVs) of the above-mentioned persons have been attached.

6. We indicate:

Ordinal number	Required information	Indication or place of indication
1	detailed description of the work given in the CRO budget grid as an unitized budget. Units` composition should be provided (number of hours and resource allocation per unit); provided in an MS Excel file, prices given in EUR, cost has to be grouped with functional areas in accordance with Table 02 of RFP no. AMB-03032023-CRO. Any cost not covered is to be added as an	

	additional cost group 'Other necessary to perform'. (Time and Material costing is acceptable). A final list of deliverables, roles and responsibilities and project timelines will be agreed in the course of signing the agreement and described in the assigned Work Oder (or equivalent). As an alternative scenario a fix price budget may be provided in addition to a unitized one.	
2	current reporting (frequency and way of updates/meetings, data format, documentation, etc.) during the course of the service	
3	a list of all study manuals, plans, guidelines and trackers that will be generated for this study	
4	a description of team structure (organizational chart)	
5	a description of project management	
6	a description of process overview	
7	a description of communication/escalation plan	
5	metrics used by a CRO and provided to the study sponsor on performance and compliance verification	
6	if the services offered are provided by direct employees of the CRO, freelance contractors, or other form of sub-vendor(s).	
7	A description of CRO's experience in the field of hematology, Phase I/II clinical studies in the last 5 years	
8	all other relevant background information and strategic approaches presenting CRO's eligibility to execute the studies	

7. We declare the execution of the subject of request for the amount of …… EUR (total fees including direct, indirect and pass throughs costs).

8. We declare that we consider ourselves bound by this offer for the time of …… calendar days.

APPENDICES TO THE QUOTATION FORM

- Detailed Budget grid
- Resumes (CVs) of the persons indicated for the performance of the order.

…….. ……

Place and date Signature of the authorized person